Patent · US Active

Crystal form H imatinib mesylate for pharmaceutical use

US8198289B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignees

Novartis AG · CH
Novartis Pharma AG · CH

Inventor

Michael Mutz · Glückstadt, DE

Key dates

Filing date	Jan 14, 2011
Grant date	Jun 12, 2012
Priority date	—
Expiry date	Jan 14, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to particular crystal forms of the methanesulfonic acid addition salt of 4-(4 -methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide,certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.